SCHEMBL30906767

SCHEMBL30906767

CC(O)c1cnc(-c2nc(NC3CCN(S(=O)(=O)c4c[nH]cn4)CC3)ncc2C(F)(F)F)s1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 19/20 0.47
▸ CDK2 P24941 19/20 0.47
▸ CCND1 P24385 14/20 0.47
▸ CDK6 Q00534 14/20 0.47
▸ CDK1 P06493 13/20 0.47
▸ CCNB1 P14635 13/20 0.47
▸ CDK4 P11802 12/20 0.47
▸ CCND3 P30281 12/20 0.47
▸ CDK7 P50613 8/20 0.47
▸ CCNH P51946 8/20 0.47
▸ MNAT1 P51948 8/20 0.47
▸ CCNT1 O60563 7/20 0.47
▸ CDK9 P50750 7/20 0.47
▸ CCNK O75909 1/20 0.38
▸ CDK12 Q9NYV4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27213126 1.00 CCNE1 (0.47) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL27213118 0.88 CCNE1 (0.62) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30906841 0.88 CCNE1 (0.62) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL27213185 0.86 CCNE1 (0.60) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30906806 0.86 CCNE1 (0.60) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL27213132 0.86 CDK2 (0.47) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30906875 0.86 CDK2 (0.47) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30906795 0.85 CDK2 (0.62) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL27213222 0.85 CDK2 (0.62) CCNE1CDK2CCND1CDK6CDK1
SCHEMBL30906779 0.81 CCNE1 (0.61) CCNE1CDK2CCND1CDK6CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO claimed
WO-2024077216-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-04-11 — — WO disclosed
Send feedback